Core Facility

Antibodies

Prof. Dr. Ilse Hofmann

Group Leader

Welcome to the Core Facility Antibodies. We offer the production and purification of antibodies. These include: monoclonal antibodies (hybridoma technology, mouse/rat), polyclonal ABs (guinea pig) and recombinant antibodies (sequencing, engineering). Many of the antibodies produced in-house are available for internal research purposes (antibody list).

Services

monoclonal antibodies (hybridoma) | polyclonal antibodies | recombinant antibodies | purification | measurement of biomolecular interactions

 

 

 

Overview

For more than two decades we have been successfully producing antibodies against proteins and other antigens, including splice variants, mutated and modified forms. - We generate monoclonal (mouse/rat) antibodies using hybridoma technology. In addition, we also offer the production of polyclonal (guinea pig) ABs that specifically recognize antigens that elicit only minor antibody responses in mice or rats. - Our service includes the production of MABs for research projects and as diagnostic tools in histopathology. - In addition, we offer non-GMP production and purification of mABs. - Finally, we also offer sequencing, engineering and recombinant expression of antibodies. These recombinant antibodies open up new avenues in biomedical research, diagnostics and as therapeutics. - Many of the antibodies we produce are available for internal research purposes (antibody list).

Services - Information

We use state-of-the-art hybridoma technologies for production of monoclonal antibodies via the somatic fusion of lymphocytes from immunized mice or rats. We advise in the selection of antigens, immunize animals and perform screening of mother clones by e.g. ELISA, immunofluorescence or IHC. Clones having been tested successfully will be subcloned, expanded and maintained to guarantee long-time availability of materials. In addition, we provide non-GMP production and purification of antibodies.

Our service includes:

 

  • Advice in the selection of the antigen (protein/peptide)
  • Alignment analysis to check for cross-reactivity
  • Immunization of animals
  • Titer test
  • Advice in validation of antibody specificity
  • Consultation and close interaction with customers during all steps of production
     

Our workflow:

  • Fusion of lymphocytes to immortalized cell line
  • Screening of clones by ELISA/Western blot/Immunofluorescence
  • Selection of clones displaying desired specificity
  • Sub-cloning to capture stable cell lines
  • Estimation of antibody subgroup
  • Expansion and storage of positive clones
  • Supply with supernatant for your experiments
  • If required, scale up and antibody purification

 

Team

  • Prof. Dr. Ilse Hofmann

    Head of Unit

    Contact form: Message to Prof. Dr. Ilse Hofmann

    Form data is loaded ...

  • Tanja Schlechter

    Technician

    Contact form: Message to Tanja Schlechter

    Form data is loaded ...

  • Natalie Erbe-Hofmann

    Technician

    Contact form: Message to Natalie Erbe-Hofmann

    Form data is loaded ...

  • Claudia Linhard

    Technician

    Contact form: Message to Claudia Linhard

    Form data is loaded ...

  • Fabian Zimmermann

    Technician

    Contact form: Message to Fabian Zimmermann

    Form data is loaded ...

  • Dr. Frank Schwarz

    Biochemist & Computer Scientist

    Contact form: Message to Dr. Frank Schwarz

    Form data is loaded ...

Selected Publications

Kim M., Reidenbach S., Schlechter T., Rothmann AC., Will R., Hofmann I. Plakophilin 1-deficient cells up-regulate cytokine expression and this correlates with immune cell recruitment in prostatic tumors. (2023) FEBS Apr.290(7)1907-1919 PMID: 36380691

Nikitina E, Burk-Körner A, Wiesenfarth M, Alwers E, Heide D, Tessmer C, Ernst C, Krunic D, Schrotz-King P, Chang-Claude J, von Winterfeld M, Herpel E, Brobeil A, Brenner H, Heikenwalder M, Hoffmeister M, Kopp-Schneider A, Bund T. Bovine meat and milk factor protein expression in tumor-free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival. (2023) Mol Oncol. Feb 22. PMID: 36811271  doi: 10.1002/1878-0261.13390

Phillips E., Balss J., Bethke F., Pusch S., Christen S., Hielscher T., Schnölzer M., Fletcher MNC., Habel A., Tessmer C., Brenner LM., Göttmann M., Capper D., Herold-Mende C., von Deimling A., Fendt SM., Goidts V. PFKFB4 interacts with FBXO28 to promote HIF-1α signaling in glioblastoma. Oncogenesis. 2022 Sep 17;11(1):57 PMID: 36115843

 

Sicong Ma, Roger Sandhoff, Xiu Luo, Fuwei Shang, Qiaozhen Shi, Zhaolong Li, Jingxia Wu, Yanan Ming, Frank Schwarz, Alaa Madi, Nina Weisshaar, Alessa Mieg, Marvin Hering, Ferdinand Zettl, Xin Yan, Kerstin Mohr, Nora Ten Bosch, Zhe Li, Gernot Poschet, Hans-Reimer Rodewald, Nina Papavasiliou, Xi Wang, Pu Gao, Guoliang Cui
Serine enrichment in tumors promotes regulatory T cell accumulation through sphinganine-mediated regulation of c-Fos
Sci Immunol. 2024 Apr 19;9(94):eadg8817. doi: 10.1126/sciimmunol.adg8817. Epub 2024 Apr 19. PMID:38640251

Pfefferle S , Schöpf J, Kögl M, Friedel C, Müller M, Carbajo-Lozoya J, Stellberger T, von Dall'Armi E, Herzog P, Kallies S, Niemeyer D, Vanessa Ditt V, Kuri T, Züst R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Wessels C, Pöhlmann S, Haas J, Drosten Christian, von Brunn A
The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors
PLoS Pathog. 2011 Oct;7(10):e1002331. Epub 2011 Oct 27 PMID: 22046132

Get in touch with us

Two scientists looking at a computer monitor
Prof. Dr. Ilse Hofmann
Group Leader
Contact form: Message to Prof. Dr. Ilse Hofmann

Form data is loaded ...